Michigan Pharmacy and Therapeutics Committee  
June 13, 2017 6:00 PM  
Kellogg Center, East Lansing, Michigan  

Agenda  

I. Introductions  
II. Conflict of Interest Statement  
III. Approval of the Agenda  
IV. Approval of Minutes of March 2017 Meeting  
V. MDHHS Update  
   A. Naloxone standing order  
   B. Legislative update  
   C. Medical pharmacy  
   D. Utilization updates  
      1. Short-acting beta agonists  
      2. Entresto  
   E. Clinical Trial Updates  

VI. Old Business  
   A. Uptravi – Griphon study results  
   B. Jardiance  

New Drugs  
1. Adlyxin (lixisenatide) subcutaneous injection – [PDL class: Diabetes: Incretin Mimetics; non-preferred]  
2. Basaglar (insulin glargine) subcutaneous injection - [PDL class: Diabetes: Insulins, Basal; non-preferred]  
3. Emflaza (deflazacort) tablets and oral suspension - [Not a PDL Class; Add to MPPL with PA]  
4. Eucrisa (crisaboraole) topical ointment - [PDL class: Dermatologicals: Topical Immunomodulators; non-preferred]  
5. Impavido (miltefosine) capsules – [Not a PDL Class; Add to MPPL with PA]  
6. Rayaldee (calcifediol) ER capsules – [Not a PDL Class; Add to MPPL with PA]  
7. Soliqua (insulin glargine/lixisenatide) subcutaneous injection – [PDL class: Diabetes: Incretin Mimetic Combinations; non-preferred]  
8. Vemlidy (tenofovir alafenamide) tablets – [Not a PDL Class; Add to MPPL with PA]  
9. Xermelo (telotristat ethyl) tablets – [Not a PDL Class; Add to MPPL with PA]
10. Xultophy (insulin degludec/liraglutide) subcutaneous injection - [PDL class: Diabetes: Incretin Mimetic Combinations; non-preferred]

Review of Preferred Drug List Classes

A. Antibiotics/Anti-Infectives:
   1. Antibiotics - Inhaled
   a. No change to the current classification of drug products
   2. Antifungals – Oral
   a. No change to the current classification of drug products
   3. Antifungals – Topical
   a. Move clotrimazole-betamethasone lotion to non-preferred.
   4. Antivirals – Herpes
   a. Move acyclovir suspension to preferred
   b. Move Zovirax (acyclovir) suspension to non-preferred
   5. Antivirals – Influenza
   a. No change to the current classification of drug products
   6. Antivirals – Topical
   a. No change to the current classification of drug products
   7. Cephalosporin – 1st Generation
   a. No change to the current classification of drug products
   8. Cephalosporin – 2nd Generation
   a. No change to the current classification of drug products
   9. Cephalosporin – 3rd Generation
   a. No change to the current classification of drug products
   10. Hepatitis C
    a. No change to the current classification of drug products
   11. Hepatitis C – Direct-Acting Antivirals
    a. No change to the current classification of drug products
   12. Macrolide
    a. Move erythromycin base tablets to non-preferred
   13. Oxaladinones
    a. No change to the current classification of drug products
   14. Quinolones
    a. Move ciprofloxacin suspension to non-preferred
   15. Ophthalmic Fluoroquinolones
    a. No change to the current classification of drug products
   16. Ophthalmic Macrolides
    a. No change to the current classification of drug products
   17. Otic Quinolones
    a. No change to the current classification of drug products
   18. Topical Antibiotics
    a. No change to the current classification of drug products
   19. Gastrointestinal Antibiotics
    a. No change to the current classification of drug products
B. Asthma/COPD/Allergy:

1. Anticholinergic Agents – Short Acting
   a. No change to the current classification of drug products

2. Anticholinergic Agents – Long Acting
   a. No change to the current classification of drug products

3. Beta Adrenergic and Anticholinergic Combinations
   a. Move Stioltto (tiotropium/olodaterol) to preferred
   b. Move Combivent (ipratropium/albuterol) to non-preferred

4. Beta Adrenergics – Short Acting
   a. No change to the current classification of drug products

5. Beta Adrenergics – Long Acting
   a. No change to the current classification of drug products

6. Beta Adrenergics for Nebulizers
   a. No change to the current classification of drug products

7. Beta Adrenergic/ Corticosteroid Inhaler Combinations
   a. Move Advair HFA (fluticasone/salmeterol) to non-preferred

8. Phosphodiesterase-4 (PDE-4) Inhibitors
   a. No change to the current classification of drug products

9. Inhaled Glucocorticoids
   a. Move Flovent Diskus (fluticasone) to non-preferred

10. Leukotriene Inhibitors
    a. No change to the current classification of drug products

11. Antihistamines – 2nd Generation
    a. No change to the current classification of drug products

12. Nasal Anticholinergics
    a. No change to the current classification of drug products

13. Nasal Antihistamines
    a. Move azelastine (generic for Astepro and Astelin) to preferred
    b. Move Astepro (azelastine) to non-preferred

14. Nasal Steroids
    a. Move mometasone (generic for Nasonex) to non-preferred.

Public Comments: Comments are limited to 5 minutes, regardless of the number of medications to be presented. If there are more than 12 presenters, the time allotment will be prorated to accommodate the number of requests within a one hour timeframe.

1. Tom Constance, PharmD, Gilead Sciences, re. Cayston
2. Dr. Thomas Board, Neurocrine Biosciences, re. Ingrezza
3. Dr. Nilay Patel, Lexicon Pharmaceuticals, re. Xermelo
4. Kristen Dial, PharmD, Novo Nordisk, Inc., re. Xultophy
5. Ndidi Yaucher, Novartis, re. Cosentyx
6. Melanie Brenner, PharmD, OPKO Pharmaceuticals, re. Rayaldee
7. Mary Pat Petrillo, PharmD, Janssen Health Economics & Outcomes Research, re. Invokana
9. Donna Beydoun, PharmD, Merck, re. Zepatier
10. Myrtha Gregoire-Bottex, MD, Cystic Fibrosis Center, re. inhaled antibiotics

Next Meeting: Tuesday, September 12, 2017
Location: Kellogg Center
Drug Classes: Diabetes
Gastrointestinal
Miscellaneous